Hammond ME, Hayes DF, Dowsett M, Allred DC, Hagerty KL, Badve S et al (2010) American society of clinical oncology/college of american pathologists guideline recommendations for immunohistochemical testing of estrogen and progesterone receptors in breast cancer. J Clin Oncol 28(16):2784–2795

Article  PubMed  PubMed Central  Google Scholar 

Allison KH, Hammond MEH, Dowsett M, McKernin SE, Carey LA, Fitzgibbons PL et al (2020) Estrogen and progesterone receptor testing in breast cancer: ASCO/CAP guideline update. J Clin Oncol 38(12):1346–1366

Article  PubMed  Google Scholar 

Reinert T, Cascelli F, de Resende CAA, Gonçalves AC, Godo VSP, Barrios CH (2022) Clinical implication of low estrogen receptor (ER-low) expression in breast cancer. Front Endocrinol (Lausanne) 13:1015388

Article  PubMed  Google Scholar 

Iwamoto T, Booser D, Valero V, Murray JL, Koenig K, Esteva FJ et al (2012) Estrogen receptor (ER) mRNA and ER-related gene expression in breast cancers that are 1% to 10% ER-positive by immunohistochemistry. J Clin Oncol 30(7):729–734

Article  PubMed  Google Scholar 

Villegas SL, Nekljudova V, Pfarr N, Engel J, Untch M, Schrodi S et al (2021) Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors-an analysis of 2765 patients from neoadjuvant clinical trials. Eur J Cancer 148:159–170

Article  CAS  PubMed  Google Scholar 

Schmid P, Cortes J, Dent R, McArthur H, Pusztai L, Kümmel S et al (2024) Overall survival with pembrolizumab in early-stage triple-negative breast cancer. N Engl J Med. https://doi.org/10.1056/NEJMoa2409932

Article  PubMed  Google Scholar 

Cardoso F, O’Shaughnessy J, McArthur H, al e. (2024) Abstract GS01–02: Phase 3 study of neoadjuvant pembrolizumab or placebo plus chemotherapy, followed by adjuvant pembrolizumab or placebo plus endocrine therapy for early-stage high-risk ER+/HER2− breast cancer: KEYNOTE-756. Cancer Reearch. https://doi.org/10.1158/1538-7445.SABCS23-GS01-02

Article  Google Scholar 

Loi S, Curigliano G, Salgado R, Díaz RIR, Delaloge S, García CIR, Kok M, Saura C, Harbeck N, Mittendorf E, Yardley D, Pusztai L, Zaizar AS, Ungureanu A, Ades F, Chandra R, Nathani R, Pacius M, Spires T, Jenny W, McArthur H (2024) Abstract GS01–01: biomarker results in high-risk estrogen receptor positive, human epidermal growth factor receptor 2 negative primary breast cancer following neoadjuvant chemotherapy ± nivolumab: an exploratory analysis of checkmate 7FL. Cancer Res. https://doi.org/10.1158/1538-7445.SABCS23-GS01-01

Article  Google Scholar 

Bonadio RC, de Sousa IM, Balint FC, Comini ACM, Tavares MC, Madasi F et al (2024) Dose dense versus 3 weekly AC during neoadjuvant chemoimmunotherapy for triple negative breast cancer. NPJ Breast Cancer 10(1):73

Article  CAS  PubMed  PubMed Central  Google Scholar 

Bonadio RC, Estevez-Diz MDP (2021) Perspectives on PARP inhibitor combinations for ovarian cancer. Front Oncol 11:754524

Article  CAS  PubMed  PubMed Central  Google Scholar 

Schmid P, Cortes J, Pusztai L, McArthur H, Kümmel S, Bergh J et al (2020) Pembrolizumab for early triple-negative breast cancer. N Engl J Med 382(9):810–821

Article  CAS  PubMed  Google Scholar 

Cherifi F, Cabel L, Bousrih C, Volant E, Dalenc F, Mery B, AuvrayKuentz M, Alexandre M, Benistant L, Leheurteur M, Bailleux C, Debled M, Frenel J-S, Loirat D, Bidard FC, Aho S, Glenet A, Ribeiro Mourato JTL, Christy F, Emile G (2024) 238MO-PROMENADE: pembrolizumab for early triple negative ER-low breast caNcer, reAl worlD frEnch cohort. Ann Oncol. https://doi.org/10.1016/j.annonc.2024.08.181

Article  Google Scholar 

Sharma P, Stecklein SR, Yoder R, Staley JM, Schwensen K, O’Dea A et al (2024) Clinical and biomarker findings of neoadjuvant pembrolizumab and carboplatin plus docetaxel in triple-negative breast cancer: NeoPACT phase 2 clinical trial. JAMA Oncol 10(2):227–235

Article  PubMed  Google Scholar 

Choong GMY, Hoskin TL, Boughey JC, Ingle JN, Goetz MP (2024) The impact of adjuvant endocrine therapy (AET) omission in ER-low (1–10%) early-stage breast cancer. J Clin Oncol. https://doi.org/10.1200/JCO.2024.42.16_suppl.513

Article  Google Scholar